Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world therapeutic drug monitoring of BRAF and MEK inhibitors in melanoma
NL-OMON38707Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vemurafenib, dabrafenib + trametinib and trametinib in melanoma and cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Pharmacokinetic variability and relationship to outcome and toxicity. Planned start Jun 2013; status: not yet recruiting.
02
Drugs
vemurafenibdabrafenib + trametinibtrametinib
03
Conditions
melanomacancer
Beyond the preview
Go deeper on NL-OMON38707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38707.